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Background Adolescents with congenital heart disease (CHD) con-
stitute a growing population of individuals for whom a well-planned
and well-executed ‘‘transition process’’ is essential. Transition
program should include education about medical conditions and
promote skills in decision-making and self-care. To improve their
level of health related knowledge, a structured education pro-
gram was implemented in a transition CHD program. This study
aimed 1/to evaluate level of knowledge of adolescents who received
structured CHD education as compared to adults who did not,
2/to evaluate whether patients who received structured education
improve their knowledge.
Methods and results 42 adolescents (16± 2 years old, 21 girls)
were included in a structured CHD education program and were
compared to 22 adults (33± 7, 6women) with CHD who have
never followed education program. Knowledge in adolescents
was assessed before and after the educational program using
questionnaire exploring speciﬁc issues related to CHD. A same ques-
tionnaire was used in non-educated adult patients. The mean total
knowledge score in the educated adolescent group was signiﬁ-
cantly higher as compared to the non-educated adult with CHD
(score = 15.6/20± 3.6 vs. 12.5± 4.5, P < 0.01). Provision of struc-
tured CHD education and female sex were determinant of higher
levels of knowledge. A signiﬁcant improvement of knowledge was
observed in adolescents group after CHD education program (range
of increase was 23 to 44%). This result was not inﬂuenced by age,
sex, education level, socio-economic status of parents and disease
complexity, and persists at 10months mean follow-up.
Conclusion A structured education program was associated with
a higher level of knowledge, above all in male CHD patients. Educa-
tion at transition period has a signiﬁcant impact on the adolescent
knowledge. Structured education program should improve adult
CHD understanding of their heart condition, and could prevent
potential complications.
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Methods Retrospective single-centre analysis of long-term post-
transplant outcome, with chart collection of clinical and
paraclinical data [this study assessed the long-term outcome of
heart (HTx) and heart-lung transplantation (HLTx) in patients with
congenital heart disease (CHD) and children with non-congenital
cardiac or pulmonary disease.]
Results From 1984 to 2013, 111 ﬁrst-HTx, 5HLTx and 6 re-HTx
were performed (62males), in patients aged 11.7± 8.2 y: 96 (79%)
aged < 18 y. Cardiopathy included 61 cardiomyopathies (50.8%),
50 CHD (41.7%), 6 retransplants (5%). HLTx included 1 Eisenmenger,
1 PPHT, and 2 pulmonary diseases. Patients with cardiomyopa-
thy were younger than CHD (8.7 y vs. 14.9 y). Seventeen (14%)
patients had circulatory mechanical support as bridge to trans-
plant. Acute rejection occurred more frequently within the ﬁrst
year post-transplant or > 5th year in non-compliant teenagers. Over-
all, 33 patients died (27%), 3.5± 4.6 y post-Tx (1 day to 16.4 y, med
1.5months), due to early multivisceral failure in 6 (18%), pulmonary
hypertension in 3 (9%), acute rejection in 7 (21%), graft coronary
disease in 6 (18%), sepsis in 5 (15%) and miscellaneous in 6. Graft
coronary disease occurred in 15 (12.4%): 4 had re-HTx, 6 died and
5 are alive. Five lymphoma occurred, 4months to 14 y after HTx,
cured in 4 (1 died). Patients survival was 85% at 1 y, 81% at 5 y, 70%
at 10 y and 61% at 20 y post-transplant. Graft survival rates were
respectively 82%, 68% and 52% at 5 y, 10 y and 20 y post-transplant.
Survival did not differ with pretransplant disease, age, gender, pre-
transplant mechanical support. Mortality was higher in patients with
coronary disease (40%) than those free from (25%).
Conclusion Long-term prognosis after HTx and HLTx is favourable.
Graft coronary disease is the main cause of failure, less frequent
than in the adult non-CHD heart-transplanted population.
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Objectives Risk markers of cardiovascular events in children with
Marfan syndrome remain little known. We assessed the prognostic
value of aortic root Z-score in patients with Marfan syndrome diag-
nosed during childhood.
Methods From the French multicenter database, 457 patients
with Marfan syndrome, diagnosed before 18 y.o., were prospectively
included in this cohort study. Echocardiographic measurements of
aortic root diameters were performed at each visit. We calculated
the Z-score of aortic root measurements using the Bichat formula.
Mean Z-score was deﬁned as the mean of the Z-score (mean ZS15)
calculated for each measurement before the age of 16.
Fig. 1 Survival estimate without cardiovascular events.
Results Median age at end of FU was 15.9 years (interquartile
10.9—20.3). FU was complete for 69.5% of patients. Median FU was
4.6 years. A cardiovascular event occurred in 17 patients (3.7%, pro-
phylactic aortic surgery n = 14, aortic dissection n = 1 and deaths
n = 2). Survival free of cardiac events was 85.1% in patients with a
mean ZS15 of the Valsalva diameter < 3 and 56.4% in patients with
a mean ZS15 of the Valsalva diameter≥ 3 (P < 0.0001 by log-rank
test) (Fig. 1). In univariate analysis, Valsalva mean ZS15≥ 3, age
at inclusion in the database, a lower heart rate and an increased
arm/height ratio were associated with an increasing risk of cardiac
events (P < 0.0001, P = 0.04, P = 0.01 and P = 0.04 respectively). After
multivariate adjustment using a cox proportional hazards model,
only Valsalva mean ZS15≥ 3 and lack of FBN1 or TGBB mutation
identiﬁed were associated with an increasing risk of cardiac events,
P < 0.0001 and P = 0.04 respectively) (Fig. 1).
Conclusion Valsalva mean ZS15 may help to identify high-risk chil-
dren.
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